Celldex Therapeutics, Inc. income statement CLDX

Annual Quarterly

In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Celldex Therapeutics, Inc. reported revenue of $22,000, down 97.0% from the same quarter a year earlier. It recorded a net loss of $73.5 million. The operating loss came to $80.6 million, an operating margin of -366468.2%. Diluted earnings per share were -$0.94.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the same quarter a year earlier.

TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Q1 FY2025
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Revenue
0
-97.3%
0
-97.0%
0
-97.8%
0
-89.7%
0
-100.0%
1
-70.8%
1
+345.5%
1
-71.6%
3
+110.3%
Research and development
279
+40.1%
68
+24.6%
73
+38.7%
75
+60.5%
63
+39.0%
54
+36.6%
53
+66.2%
47
+54.3%
45
+31.1%
Selling, general and administrative
47
+13.6%
13
+26.1%
11
+5.8%
12
+16.3%
11
+6.3%
10
+13.8%
11
+18.9%
10
+16.2%
10
+22.3%
Operating income
-326
-38.8%
-81
-26.3%
-84
-34.6%
-87
-55.6%
-74
-41.2%
-64
-37.9%
-63
-54.5%
-56
-17.6%
-52
-26.4%
Net income
-301
-74
-29.9%
-79
-81
-67
-57
—
—
—
Basic EPS
-4.34
-111.5%
-0.94
-10.6%
-1.18
-45.7%
-0.31
-67.9%
-1.01
-57.8%
-0.85
-57.4%
-0.81
-44.6%
-0.18
+18.4%
-0.64
+21.0%
Diluted EPS
-4.34
-111.5%
-0.94
-10.6%
-1.18
-45.7%
-0.31
-67.9%
-1.01
-57.8%
-0.85
-57.4%
-0.81
-44.6%
-0.18
+18.4%
-0.64
+21.0%
Weighted average shares, basic
69
-28.8%
78
+17.2%
67
+0.3%
263
+2.9%
0
+0.2%
66
+100465.0%
66
+112660.1%
255
+33.3%
0
+40.3%
Weighted average shares, diluted
69
-28.8%
78
+17.2%
67
+0.3%
263
+2.9%
0
+0.2%
66
+100465.0%
66
+112660.1%
255
+33.3%
0
+40.3%
Other measures
Depreciation and amortization
3
+1.5%
1
+3.3%
1
-1.5%
1
-0.4%
1
+4.8%
1
+9.5%
1
+11.9%
1
+7.9%
1
+2.5%
EBITDA
-322
-39.3%
-80
-26.6%
-84
-35.1%
-86
-56.4%
-73
-41.8%
-63
-38.4%
-62
-55.3%
-55
-17.8%
-51
-26.9%
Margins
Operating margin
-206,220.25%
-366,468.18%
-562,900.00%
-72,027.27%
—
-8,747.53%
-9,027.19%
-4,768.26%
-1,633.53%
Profit margin
-190,220.89%
-334,104.55%
-524,566.67%
-67,204.13%
—
-7,753.42%
—
—
—
EBITDA margin
-204,070.89%
-362,368.18%
-557,206.67%
-71,352.89%
—
-8,627.95%
-8,902.45%
-4,698.55%
-1,608.90%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
CLDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Hampton, NJ
SEC filer status
Large accelerated filer
SEC CIK
744218
Former names
AVANT IMMUNOTHERAPEUTICS INC (until Sep 29, 2008); T CELL SCIENCES INC (until Aug 21, 1998)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.